Thus, adding targeted therapies for cancers with certain mutations in early-stage disease will generally require a rigorous level of evidence from large prospective randomized controlled trials with multi-year follow-up, as was recently shown for PARP inhibitors and BRCA1- or BRCA2-derived breast cancers (18, 20). Here, BRCA2 is linked to breast carcinoma.